Midron

Midron is an Israel-based biotechnology company focused on developing disease-modifying treatments for neurodegenerative disorders, particularly Parkinson's disease. The company utilizes a proprietary platform to identify small molecules that stabilize mitochondrial membranes and prevent the toxic aggregation of proteins such as alpha-synuclein. By targeting the early stages of protein misfolding, Midron aims to halt neuronal degeneration and preserve cognitive and motor functions. The company was founded on research from the Hebrew University of Jerusalem and is currently advancing its lead candidates through pre-clinical development.